Start of publicly sponsored BMBF-Project „Development of a novel wound dressing for burns” at Europe’s leading institute for textile research ITV Denkendorf.
Foundation of Polymedics Innovations GmbH by the five leading scientists who developed SUPRATHEL® and other tissue engineering technologies.
CE mark and launch of SUPRATHEL® in Germany and Austria.
International Expansion and regulatory approvals in Switzerland, Nordics, UK, Italy, Turkey, South Africa, Mexico, Pakistan, Australia.
US – FDA 510K approval.
KFDA approval in Korea.
Inauguration of state of the art in-house production in Denkendorf, Germany.
Foundation of US subsidiary Polymedics Innovations Inc.
Today PMI develops and manufactures new technologies for the wound care sector in Denkendorf and markets its products in 30 countries around the world.
Opening of US subsidiarity in Woodstock, Georgia.
SUPRA SDRM® 510k certification in the United States.
SUPRA SDRM® product approval in the European Union.
Cooperation with PolyNovo Biomaterials Pty Ltd. for the distribution of NovoSorb® BTM in the DACH (Germany, Austria, Switzerland) region.
Christian Planck appointed as Co-CEO of PolyMedics Innovations GmbH alongside Prof. Dr. Heinrich Planck.
PMI expands the distribution of NovoSorb® BTM to Benelux and Sweden.
Product launch of the novel synthetic guided wound closure matrix SUPRA SDRM® for difficult to heal wounds.